953 – Adherence to sentinel lymph node biopsy guidelines in breast cancer: temporal trends in a real-world public reference center cohort
DOI:
https://doi.org/10.29289/259453942025V36S10953Keywords:
breast neoplasms, sentinel lymph node biopsy, neoadjuvant therapy, guideline adherence, time factorsAbstract
Introduction: Sentinel lymph node biopsy (SLNB) is the standard approach for axillary staging in clinically node-negative
breast cancer and has progressively expanded after neoadjuvant chemotherapy (NAC). However, adherence to evidencebased axillary de-escalation remains variable, particularly in public healthcare settings. Objectives: To evaluate adherence to guideline-based indications for SLNB in women with non-metastatic invasive breast cancer treated in a public
referral center and to identify factors associated with non-adherent axillary management.
Methods: A retrospective cross-sectional study was conducted including women with non-metastatic invasive breast
cancer treated at a public reference center in São Paulo, Brazil, from 2015 to 2025. The primary endpoint was agreement
between the guideline-based theoretical SLNB indication and the procedure actually performed. Secondary endpoints
included adherence by clinical setting, factors associated with non-adherence, and temporal trends.
Results: A total of 1,672 patients were analyzed. Overall, 1,298 (77.6%) were managed according to guideline-based SLNB
criteria, whereas 374 (22.4%) underwent discordant management. Adherence was higher in upfront surgery than after
NAC (80.8% vs. 67.8%; p<0.001). In the upfront setting, agreement between theoretical indication and actual practice was
moderate (κ=0.578; p<0.001), whereas in the post-NAC setting it was negligible (κ=0.028; p=0.300). In upfront surgery, older
age, lobular histology (odds ratio [OR] 6.6; 95% confidence interval [CI] 2.7–16.2), and positive SLNB (OR 6.0; 95%CI 3.7–9.9)
were independently associated with incorrect management. After NAC, the Luminal/human epidermal growth factor
receptor 2 (HER2)-positive subtype (OR 2.50; 95%CI 1.10–5.66), T3–T4 tumors (OR 3.40; 95%CI 1.45–7.98), subsequent axillary surgery (OR 6.44; 95%CI 2.91–14.26), and SLNB omission were associated with non-adherence. Adherence increased
over time, with a mean annual rise of 1.84 percentage points (R²=99.1%; p<0.001).
Conclusion: Evidence-based axillary de-escalation was well incorporated into upfront surgery but remained less consistent after NAC, supporting institutional protocols, surgical education, and improved technical resources in public practice.
Ethics: The study was approved by Plataforma Brazil (CAAE 83327324.0.0000.5463).
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marcelo Antonini, Luana Medrado Vitorino Oliveira, Andre Mattar, Felipe Zerwes, Francisco Pimentel Cavalcante, Eduardo Camargo Millen, Fabricio Palermo Brenelli, Antonio Luis Frasson

This work is licensed under a Creative Commons Attribution 4.0 International License.






